# SciSparc Ltd.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/SciSparc Ltd.).

## Overview

SciSparc Ltd. is a U.S.-listed biopharmaceutical company with operations centered in Tel Aviv, Israel, through its majority-owned subsidiary NeuroThera. Its business focuses on clinical-stage cannabinoid-based drug development for central nervous system disorders, alongside a smaller consumer product activity in hemp seed oil products sold online.

## Products & services

• SCI-110 cannabinoid-based therapy for Tourette syndrome and Alzheimer’s-related agitation
• SCI-210 cannabinoid-based therapy for autism spectrum disorder and status epilepticus
• Clinical-stage neuroscience drug development through NeuroThera
• Hemp seed oil-based products sold on Amazon Marketplace
• AI and cybersecurity opportunity evaluation through scientific advisory work

- **Clinical-stage cannabinoid therapeutics** (70%) — Drug candidates based on THC and non-psychoactive CBD for CNS and related disorders.
- **Consumer hemp seed oil products** (20%) — Hemp seed oil-based products sold through Amazon Marketplace.
- **Scientific and strategic advisory activity** (10%) — Early-stage evaluation of AI, cybersecurity, and related opportunities.

- SCI-110 for Tourette syndrome and Alzheimer's-related agitation
- SCI-210 for autism spectrum disorder and status epilepticus
- Clinical-stage cannabinoid pharmaceutical development
- Hemp seed oil-based products sold on Amazon Marketplace
- Agentic AI and cybersecurity opportunity evaluation

## Customers

SciSparc’s primary end users are patients with central nervous system and neurodevelopmental disorders, with the company’s drug programs directed toward conditions such as Tourette syndrome, Alzheimer’s-related agitation, autism spectrum disorder, and status epilepticus. Its consumer products are sold to retail buyers on Amazon Marketplace, while any AI-related activity is still exploratory and aimed at assessing commercial opportunities rather than serving a defined customer base.

- **Neurology and CNS treatment market** (primary) — Patients, caregivers, and physicians targeted by SCI-110 and SCI-210 for neurological and neurodevelopmental indications.
- **Online retail consumers** (secondary) — Consumers buying hemp seed oil-based products through Amazon Marketplace for wellness use.
- **Strategic technology counterparties** (emerging) — Potential partners or targets in AI and cybersecurity that may support future corporate development.

- Patients and caregivers in CNS disorder treatment markets
- Neurology and neuropsychiatry prescribers
- Retail consumers buying hemp seed oil online
- Amazon Marketplace shoppers
- Potential future AI/cybersecurity partners or acquirers

## Geography

The company is organized around operations in Tel Aviv, Israel, while being publicly listed in the United States on Nasdaq. Its pharmaceutical development programs are global in nature because clinical-stage drug assets can be developed and tested across multiple jurisdictions, and its consumer product sales are tied to the Amazon marketplace rather than a single country.

- Corporate and operational base in Tel Aviv, Israel
- Nasdaq listing in the United States
- Clinical development activities can span multiple trial jurisdictions
- Amazon Marketplace sales may reach customers across broad markets
- No country-level revenue disclosure provided

## Strategy

SciSparc is focused on advancing its cannabinoid-based pipeline in CNS disorders while continuing to seek development, regulatory, and partnership pathways for its programs. The company has also broadened its strategic lens to include agentic AI and cybersecurity, suggesting a corporate development approach that combines life sciences assets with optionality in adjacent technology areas.

- **Advance cannabinoid drug candidates** (medium-term) — Clinical progress is the core value driver for a development-stage pharmaceutical company.
- **Pursue regulatory and development catalysts** (short-term) — Regulatory milestones can de-risk programs and improve partnering or financing optionality.
- **Explore AI and cybersecurity opportunities** (short-term) — Broadens the company’s strategic pipeline beyond pharmaceuticals and may create new optionality.

- Advance SCI-110 and SCI-210 through clinical development
- Pursue regulatory designations and development milestones
- Use NeuroThera as the operating platform for drug programs
- Maintain optionality through AI and cybersecurity opportunity screening
- Support future financing or partnering with scientific advisory expertise

## Risks

SciSparc faces the usual development-stage pharmaceutical risks: clinical failure, regulatory delays, and uncertainty over whether its cannabinoid programs will achieve meaningful efficacy and approvals. The company also has execution risk from operating a small business with multiple initiatives, including consumer products and early-stage technology exploration, which can dilute focus and increase financing dependence.

- **Clinical development failure** [critical] — SCI-110 and SCI-210 are still investigational and may not prove effective or safe in trials.
- **Regulatory approval uncertainty** [high] — Drug candidates require successful interactions with health regulators before commercialization.
- **Financing dependence** [high] — A small development-stage company typically needs recurring capital to fund trials and operations.
- **Marketplace concentration** [medium] — Amazon-based consumer sales depend on a single platform’s policies, ranking, and competition.
- **Strategic distraction** [medium] — Adding AI and cybersecurity initiatives may pull management attention away from core biotech assets.

- Clinical trials may fail to demonstrate safety or efficacy
- Regulatory review can delay or block product development
- Small scale increases dependence on external financing
- Consumer marketplace sales face platform and competition risk
- AI/cybersecurity exploration may not convert into value

## Accounting

As a clinical-stage biotech company, SciSparc’s accounting is likely dominated by research and development expense recognition, fair value judgments for any warrants or financing instruments, and valuation of investments in subsidiaries such as NeuroThera. Investors should also watch how the company classifies and measures the value of its subsidiary stakes, because financing rounds and potential dilution can affect reported ownership interests and carrying values.

- **Research and development expense** — Measures cash burn tied to SCI-110 and SCI-210
- **Fair value measurement** — Can create volatility in non-operating results
- **Subsidiary investment accounting** — Affects balance sheet carrying value and ownership percentages
- **Revenue recognition for online sales** — Influences reported consumer product revenue and margins

- R&D expense recognition for clinical programs and trial activities
- Fair value of warrants and other financing instruments
- Valuation of NeuroThera investment and ownership changes
- Potential impairment or remeasurement of intangible assets
- Revenue recognition for Amazon Marketplace consumer sales

---

*Last updated: 2026-09-28T12:14:02.046536+00:00*